Abstract 2934
Background
MicroRNAs are examined for clinical utility in active germ cell malignancies (GCM). miR-371a-3p (miR371) has a very high specificity and high sensitivity for the detection of GCM. However, in teratoma neither tissue nor serum/plasma are miR371 positive. miR375 is overexpressed in teratoma tissue, but detectability in blood and its utility is unknown.
Methods
GCM patients (pts) enrolled from 10-2016 to 03-2019 in the GU biobank program at British Columbia Cancer were analyzed for plasma miR371/miR375 expression by RT-PCR and quantified by ΔΔCT method. Spike-in cel-miR-39-3p, miR-451 and miR-30b-5p were used as quality/internal controls. Sensitivity, specificity, PPV, NPV, AUC of the ROC of miR375 in detecting teratoma were analyzed.
Results
miR375 expression was measured in 69 pts of whom 15 (22%) had pathologically confirmed residual teratoma post-chemotherapy, 4 (6%) residual post-chemotherapy mass without teratoma, 8 (11%) no evidence of residual disease post-chemotherapy, 15 (22%) metastatic seminoma and 27 (39%) CSI with no evidence of tumor. miR375 expression was significantly higher in pts with residual teratoma-post chemotherapy than in non-teratoma (p < 0.0001). Concurrent miR371 and miR375 expression was evaluated in 17 pts with metastatic nonseminoma prior to and post-chemotherapy. miR371 correlated with viable GCM and disappeared after chemotherapy in all but one pt (presenting residual choriocarcinoma). Post-chemotherapy miR375 was unchanged or increased from pre-chemotherapy samples in 85% of pts with pathologically confirmed post-chemotherapy teratoma and remained low in 90% of patients with either complete response or non-teratoma after chemotherapy. Sensitivity of miR375 was 93% (95% CI: 68-99), specificity 75% (95% CI: 43-95), NPV 90% (95% CI 95%: 57-98), PPV 82% (CI 95%: 63-93) and the AUC of miR375 in the post-chemotherapy setting was 0.93 (95% CI: 0.83-1.0; p < 0.0001).
Conclusions
miR375 is overexpressed and detectable in the plasma of pts with teratoma while its expression is significantly lower in nonseminoma pts without teratoma or in seminoma. The evaluation of miR371/miR375 may be clinically useful to guide therapeutic decisions (surgery or chemotherapy). Larger studies are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract